{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:54:10Z","timestamp":1793051650332,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T00:00:00Z","timestamp":1595548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T00:00:00Z","timestamp":1595548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Bill and Melinda Gates Foundation through the Noguchi Memorial Institute for Medical Research"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Detection of HIV-1 transmitted drug resistance (TDR) and subtype diversity (SD) are public health strategies to assess current HIV-1 regimen and ensure effective therapeutic outcomes of antiretroviral therapy (ART) among HIV-1 patients. Globally, limited data exist on TDR and SD among blood donors. In this study, drug resistance mutations (DRMs) and SD amongst HIV-1 sero-positive blood donors in Accra, Ghana were characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Purposive sampling method was used to collect 81 HIV sero-positive blood samples from the Southern Area Blood Center and confirmed by INNO-LIA as HIV-1 and\/or HIV-2. Viral RNA was only extracted from plasma samples confirmed as HIV-1 positive. Complementary DNA (cDNA) was synthesized using the RNA as a template and subsequently amplified by nested PCR with specific primers. The expected products were verified, purified and sequenced. Neighbour-joining tree with the Kimura\u2019s 2-parameter distances was generated with the RT sequences using Molecular Evolutionary Genetic Analysis version 6.0 (MEGA 6.0).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Out of the 81 plasma samples, 60 (74%) were confirmed as HIV-1 sero-positive by INNO-LIA HIVI\/II Score kit with no HIV-2 and dual HIV-1\/2 infections. The remaining samples, 21 (26%) were confirmed as HIV sero-negative. Of the 60 confirmed positive samples, (32) 53% and (28) 47% were successfully amplified in the RT and PR genes respectively. Nucleotide sequencing of amplified samples revealed the presence of major drug resistance mutations in two (2) samples; E138A in one sample and another with K65R. HIV-1 Subtypes including subtypes A, B, CRF02_AG and CRF09_cpx were found.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study found major drug resistance mutations, E138A and K65R in the RT gene that confer high level resistance to most NNRTIs and NRTI respectively. CRF02_AG was most predominant, the recorded percentage of subtype B and the evolutionary relationship inferred by phylogenetic analysis may suggest possible subtype importation. However, a more prospective and detailed analysis is needed to establish this phenomenon. The data obtained would inform the selection of drugs for ART initiation to maximize therapeutic options in drug-na\u00efve HIV-1 patients in Ghana.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12985-020-01386-y","type":"journal-article","created":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T05:04:31Z","timestamp":1595567071000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Transmitted drug resistance mutations and subtype diversity amongst HIV-1 sero-positive voluntary blood donors in Accra, Ghana"],"prefix":"10.1186","volume":"17","author":[{"given":"Billal Musah","family":"Obeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn Yayra","family":"Bonney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Asamoah-Akuoko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas Israel","family":"Nii-Trebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gifty","family":"Mawuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher Zaab-Yen","family":"Abana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwamena William Coleman","family":"Sagoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,24]]},"reference":[{"key":"1386_CR1","volume-title":"World AIDS Day Global Report","author":"WHO","year":"2017","unstructured":"WHO. World AIDS Day Global Report. (2017). http:\/\/www.who.int. Accessed 13 Dec 2017."},{"key":"1386_CR2","volume-title":"HIV\/AIDS in Ghana: Background, Projections, Impacts, Interventions and Policy","author":"NACP","year":"2000","unstructured":"NACP. HIV\/AIDS in Ghana: Background, Projections, Impacts, Interventions and Policy. 3rd ed; 2000. http:\/\/www.policyproject.com\/pubs\/countryreports\/gha_aim3rded.pdf. Accessed 13 Dec 2017.","edition":"3"},{"key":"1386_CR3","volume-title":"Country factsheets, Ghana, 2017","author":"UNAIDS","year":"2018","unstructured":"UNAIDS. Country factsheets, Ghana, 2017. (2018). https:\/\/www.unaids.org\/en\/regionscountries\/countries\/ghana. Accessed 17 Dec 2018."},{"key":"1386_CR4","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1186\/1471-2334-13-517","volume":"13","author":"M Kiptoo","year":"2013","unstructured":"Kiptoo M, Brooks J, Lihana RW, Sandstrom P, Ng\u2019ang\u2019a Z, Kinyua J, et al. HIV-1 drug resistance-associated mutations among HIV-1 infected drug-na\u00efve antenatal clinic attendees in rural Kenya. BMC Infect Dis. 2013;13:517.","journal-title":"BMC Infect Dis"},{"key":"1386_CR5","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1056\/NEJM199803263381301","volume":"338","author":"FJ Palella","year":"1998","unstructured":"Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with human immunodeficiency virus infection: HIV outpatient study investigators. N Engl J Med. 1998;338:853\u201360.","journal-title":"N Engl J Med"},{"key":"1386_CR6","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1097\/01.aids.0000131310.52526.c7","volume":"18","author":"DD Richman","year":"2004","unstructured":"Richman DD, Morton SC, Wrin T, Hellmann N, Berry S, Shapiro M, et al. The prevalence of antiretroviraldrug resistance in the United States. AIDS. 2004;18:1393\u2013401.","journal-title":"AIDS"},{"key":"1386_CR7","volume-title":"Transmitted HIV-1 drug resistance in Africa","author":"RL Hamers","year":"2014","unstructured":"Hamers RL. Transmitted HIV-1 drug resistance in Africa. Lusaka: 8th INTEREST workshop; 2014."},{"issue":"5","key":"1386_CR8","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S1473-3099(11)70032-9","volume":"11","author":"L Wittkop","year":"2011","unstructured":"Wittkop L, Gunthard HF, De Wolf F, Dunn D, Cozzi-Lepri A, De Luca A, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011;11(5):363\u201371.","journal-title":"Lancet Infect Dis"},{"key":"1386_CR9","volume-title":"Report on the global epidemic","author":"UNAIDS\/WHO","year":"2009","unstructured":"UNAIDS\/WHO. Report on the global epidemic. 2009. Available at www.unaids.org\/en\/HIV_data\/2009GlobalReport\/default.asp. Accessed 13 Feb 2016."},{"key":"1386_CR10","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1086\/420789","volume":"189","author":"HS Weinstock","year":"2004","unstructured":"Weinstock HS, Zaidi I, Heneine W, Bennett D, Garcia-Lerma JG, Douglas JM, et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis. 2004;189:2174\u201380.","journal-title":"J Infect Dis"},{"key":"1386_CR11","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1086\/432916","volume":"192","author":"AM Wensing","year":"2005","unstructured":"Wensing AM, Van de Vijver DA, Angarano G, Asj\u00f6 B, Balotta C, Boeri E, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management, SPREAD Programme. J Infect Dis. 2005;192:958\u201366.","journal-title":"J Infect Dis"},{"key":"1386_CR12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jcv.2007.07.016","volume":"40","author":"KWC Sagoe","year":"2007","unstructured":"Sagoe KWC, Dwidar M, Lartey M, Boamah I, Agyei AA, et al. Variability of the human immunodeficiency virus type 1 polymerase gene from treatment naive patients in Accra, Ghana. J Clin Virol. 2007;40:163\u20137.","journal-title":"J Clin Virol"},{"issue":"7","key":"1386_CR13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.5897\/JAHR12.008","volume":"4","author":"JAM Brandful","year":"2012","unstructured":"Brandful JAM, Candotti D, Allain J-P. Genotypic diversity and mutation profile of HIV-1 strains in antiretroviral treatment (ART) \u2013Na\u00efve Ghanaian patients and implications for antiretroviral treatment (ART). J AIDS HIV Res. 2012;4(7):187\u201397.","journal-title":"J AIDS HIV Res"},{"issue":"2","key":"1386_CR14","first-page":"82","volume":"47","author":"EY Bonney","year":"2013","unstructured":"Bonney EY, Ntim NAA, Addo-Yobo F, Bondzie P, Aryee KE, Barnor JS, et al. Low level of transmitted HIV drug resistance at two HIV care Centres in Ghana: a threshold survey. Ghana Med J. 2013;47(2):82\u20136.","journal-title":"Ghana Med J"},{"key":"1386_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0071972","volume":"8","author":"NI Nii-Trebi","year":"2013","unstructured":"Nii-Trebi NI, Ibe S, Barnor JS, Ishikawa K, Brandful JAM, Ofori SB, et al. HIV-1 drug-resistance surveillance among treatment-experienced and treatment-Na\u0131ve patients after the implementation of antiretroviral therapy in Ghana. PLoS One. 2013;8:1\u20138.","journal-title":"PLoS One"},{"key":"1386_CR16","volume-title":"Update: Active involvement of young people is key to ending the AIDS epidemic by 2030","author":"UNAIDS","year":"2015","unstructured":"UNAIDS. \u2018Update: Active involvement of young people is key to ending the AIDS epidemic by 2030\u2019. 2015. https:\/\/www.avert.org\/professionals\/hiv-social-issues\/key-affected-populations\/young-people#footnote1_qzpzzqd. Accessed 21 Mar 2017."},{"issue":"1","key":"1386_CR17","first-page":"27","volume":"3","author":"ML Villahermosa","year":"2000","unstructured":"Villahermosa ML, Thomson M, V\u00e1zquez de Parga E, Cuevas MT, Contreras G, P\u00e9rez-Alvarez L, et al. Improved conditions for extraction and amplificationof human immunodeficiency virus type 1RNA from plasma samples with low viral load. J Hum Virol. 2000;3(1):27\u201334.","journal-title":"J Hum Virol"},{"key":"1386_CR18","doi-asserted-by":"crossref","first-page":"113","DOI":"10.7883\/yoken.JJID.2007.113","volume":"60","author":"S Fujisaki","year":"2007","unstructured":"Fujisaki S, Fujisaki S, Ibe S, Asagi T, Itoh T, Yoshida S, et al. Performance and quality assurance of genotypic drug-resistant testing for human immunodeficiency virus type 1 in Japan. Jpn J Infect Dis. 2007;60:113\u20137.","journal-title":"Jpn J Infect Dis"},{"key":"1386_CR19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.19070\/2330-0027-160004","volume":"4","author":"NI Nii-Trebi","year":"2016","unstructured":"Nii-Trebi NI, Barnor JS, Obeng BM, Ampofo WK. Epidemiologic dominance of HIV-1 subtype CRF02_AG in Ghana: preliminary virological evidence of increasing association with new infections. Int J Virol Stud Res. 2016;4:22\u20138.","journal-title":"Int J Virol Stud Res"},{"key":"1386_CR20","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1097\/00002030-200405210-00017","volume":"18","author":"L Fischetti","year":"2004","unstructured":"Fischetti L, Opare-Sem O, Candotti D, Lee H, Allain J-P. Higher viral load may explain the dominance of CRF02_AG in the molecular epidemiology of HIV in Ghana. AIDS. 2004;18:1208\u201310.","journal-title":"AIDS"},{"key":"1386_CR21","first-page":"A18","volume":"16","author":"M Haddad","year":"2011","unstructured":"Haddad M, Napolitano LA, Paquet AC, Evans MD, Petropoulos CJ, Whitcomb J, et al. Impact of HIV-1 reverse transcriptase E138 mutations on rilpivirine drug susceptibility. Antivir Ther. 2011;16:A18.","journal-title":"Antivir Ther"},{"key":"1386_CR22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/QAI.0b013e3182237f74","volume":"58","author":"L Tambuyzer","year":"2011","unstructured":"Tambuyzer L, Nijs S, Daems B, Picchi G, Vingerhoets J. Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine. J Acquir Immune Defic Syndr. 2011;58:18\u201322.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1386_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.4314\/gmj.v51i1.4","volume":"51","author":"A Martin-Odoom","year":"2017","unstructured":"Martin-Odoom A, Adiku T, Delgado E, Lartey M, Ampofo WK. Occurrence of transmitted HIV-1 drug resistance among drug-na\u00efve pregnant women in selected HIV care centers in Ghana. Ghana Med J. 2017;51:20\u20133.","journal-title":"Ghana Med J"},{"key":"1386_CR24","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.jinf.2010.06.008","volume":"61","author":"C Stephan","year":"2010","unstructured":"Stephan C, Dauer B, Bickel M, Haberl A, Locher L, Muller A. Intensification of a failing regimen with zidovudine may cause sustained virologic suppression in the presence of re-sensitizing mutations including K65R. J Infect. 2010;61:346\u201350.","journal-title":"J Infect"},{"key":"1386_CR25","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1093\/jac\/dkm082","volume":"59","author":"CL Booth","year":"2007","unstructured":"Booth CL, Geretti AM. Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother. 2007;59:1047\u201356.","journal-title":"J Antimicrob Chemother"},{"key":"1386_CR26","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1089\/088922202760072357","volume":"18","author":"S Mamadou","year":"2002","unstructured":"Mamadou S, Montavon C, Ben A, Djibo A, Rabiou S, M\u2019Boup S, et al. Predominance of CRF02-AG and CRF06-cpx in Niger, West Africa. AIDS Res Hum Retrovirus. 2002;18:723\u20136.","journal-title":"AIDS Res Hum Retrovirus"},{"key":"1386_CR27","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1742-4690-3-40","volume":"3","author":"HF Njai","year":"2006","unstructured":"Njai HF, Gali Y, Vanham G. The predominance of human immunodeficiency virus type 1 (HIV-1) circulating recombinant form 02 (CRF02_AG) in west Central Africa may be related to its replicative fitness. Retrovirol. 2006;3:40.","journal-title":"Retrovirol"},{"key":"1386_CR28","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1089\/aid.1994.10.561","volume":"10","author":"J Louwagie","year":"1994","unstructured":"Louwagie J, Delwart EL, Mullins JI, McCutchan FE, Eddy G, Burke DS. Genetic analysis of HIV-1 isolates from Brazil reveals the presence of two distinct genotypes. AIDS Res Hum Retrovirus. 1994;10:561\u20137.","journal-title":"AIDS Res Hum Retrovirus"},{"key":"1386_CR29","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1128\/JVI.69.1.263-271.1995","volume":"69","author":"J Louwagie","year":"1995","unstructured":"Louwagie J, Janssens W, Mascola J, Heyndrickx L, Hegerich P, McCutchan FE, et al. Genetic diversity of the envelope glycoprotein from human immunodeficiency virus type 1 isolates of african origin. J Virol. 1995;69:263\u201371.","journal-title":"J Virol"},{"key":"1386_CR30","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1097\/00002030-200212060-00012","volume":"16","author":"S Deroo","year":"2002","unstructured":"Deroo S, Robert I, Fontaine E, Lambert C, Plesseria JM, Arendt V, et al. HIV-1 subtypes in Luxembourg, 1983-2000. AIDS. 2002;16:2461\u20137.","journal-title":"AIDS"},{"key":"1386_CR31","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1097\/00126334-200408150-00013","volume":"36","author":"ID Tatt","year":"2004","unstructured":"Tatt ID, Barlow KL, Clewley JP, Gill ON, Parry JV. Surveillance of HIV-1 subtypes among heterosexuals in England and Wales, 1997-2000. J Acquir Immune Defic Syndr. 2004;36:1096\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1386_CR32","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S1473-3099(10)70186-9","volume":"11","author":"DM Tebit","year":"2011","unstructured":"Tebit DM, Arts EJ. Tracking a century of global expansion and evolution of HIV to drive understanding and to combat disease. Lancet Infect Dis. 2011;11:45\u201356.","journal-title":"Lancet Infect Dis"},{"key":"1386_CR33","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.molmed.2011.12.001","volume":"18","author":"J Hemelaar","year":"2012","unstructured":"Hemelaar J. The origin and diversity of the HIV-1 pandemic. Trends Mol Med. 2012;18:182\u201392.","journal-title":"Trends Mol Med"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-020-01386-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-020-01386-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-020-01386-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T14:34:43Z","timestamp":1723300483000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-020-01386-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,24]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1386"],"URL":"https:\/\/doi.org\/10.1186\/s12985-020-01386-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-21810\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-21810\/v1","asserted-by":"object"}]},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,24]]},"assertion":[{"value":"14 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol was approved by the Ethics and Protocol Review Committee of the College of Health Sciences, University of Ghana (CHS-Et\/M.1 \u2013 P 3.2\/2016\u20132017). Approval to select HIV positive samples was also obtained from the NBS (NBSGRD\/160929\/01).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The NBS has given the consent to publish the results without personal identification.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No competing interest exist.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"114"}}